| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $5,426 | 2 | 100 |
| Ryan Barbara | director | 0 | $0 | 2 | $5,426 | $-5,426 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Over the last 12 months, insiders at MiNK Therapeutics, Inc. have bought $0 and sold $5,426 worth of MiNK Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at MiNK Therapeutics, Inc. have bought $5.86M and sold $50,138 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 429 shares for transaction amount of $472 was made by AGENUS INC (10 percent owner) on 2023‑10‑16.
| 2026-03-02 | Sale | Ryan Barbara | director | 100 0.0021% | $10.83 | $1,083 | -1.74% | |
| 2026-02-27 | Sale | Ryan Barbara | director | 400 0.0085% | $10.86 | $4,343 | -3.70% | |
| 2023-10-16 | AGENUS INC | 10 percent owner | 429 0.0012% | $1.10 | $472 | -15.91% | ||
| 2023-10-13 | AGENUS INC | 10 percent owner | 19,373 0.0561% | $1.10 | $21,310 | -15.68% | ||
| 2023-10-12 | AGENUS INC | 10 percent owner | 3,173 0.0089% | $1.10 | $3,488 | -18.60% | ||
| 2023-10-04 | AGENUS INC | 10 percent owner | 15,001 0.0465% | $1.09 | $16,380 | -18.42% | ||
| 2023-08-29 | AGENUS INC | 10 percent owner | 29,678 0.0826% | $1.52 | $45,016 | -39.05% | ||
| 2023-08-28 | AGENUS INC | 10 percent owner | 12,808 0.0371% | $1.45 | $18,570 | -33.52% | ||
| 2023-08-24 | AGENUS INC | 10 percent owner | 170,244 0.4482% | $1.54 | $262,908 | -38.08% | ||
| 2023-05-11 | AGENUS INC | 10 percent owner | 23,361 0.0606% | $1.43 | $33,348 | -35.19% | ||
| 2023-05-10 | AGENUS INC | 10 percent owner | 22,065 0.0649% | $1.51 | $33,296 | -30.46% | ||
| 2023-05-05 | Sale | ARMEN GARO H | director | 100,000 0.1767% | $0.95 | $94,850 | -31.96% | |
| 2023-05-05 | AGENUS INC | 10 percent owner | 100,200 0.1772% | $0.95 | $95,100 | -31.96% | ||
| 2023-05-05 | AGENUS INC | 10 percent owner | 200 0.0005% | $1.25 | $250 | -31.96% | ||
| 2023-05-04 | AGENUS INC | 10 percent owner | 21,473 0.0618% | $1.22 | $26,246 | -13.60% | ||
| 2023-05-03 | AGENUS INC | 10 percent owner | 128,689 0.3494% | $1.08 | $138,843 | -7.26% | ||
| 2023-05-02 | ARMEN GARO H | director | 100,000 0.3138% | $0.95 | $94,850 | +23.03% | ||
| 2022-07-18 | WIINBERG ULF | 3,339 0.0098% | $1.33 | $4,438 | +60.26% | |||
| 2021-10-19 | AGENUS INC | 10 percent owner | 1.4M 4.2248% | $12.00 | $16.8M | -79.46% |
| Ryan Barbara | director | 21906 0.4667% | $238,775.40 | 0 | 2 | |
| AGENUS INC | 10 percent owner | 21772863 463.8292% | $237.32M | 14 | 0 | <0.0001% |
| ARMEN GARO H | director | 1866400 39.7601% | $20.34M | 1 | 1 | +23.03% |
| WIINBERG ULF | 281639 5.9998% | $3.07M | 1 | 0 | +60.26% |
$5,354,267 | 110 | -35.34% | $55.73M | |
$1,695,621 | 55 | 17.90% | $57.08M | |
$103,288,323 | 51 | 4.78% | $49.35M | |
$693,326 | 47 | -16.18% | $49.32M | |
$24,478,755 | 37 | -34.59% | $49.31M | |
$38,601,028 | 29 | 1.18% | $46.86M | |
$555,628 | 21 | 43.52% | $45.47M | |
$1,602,584 | 20 | 15.26% | $63.89M | |
MiNK Therapeutics, Inc. (INKT) | $17,594,514 | 16 | -20.37% | $51.17M |
$277,862 | 15 | 59.79% | $56.4M | |
$3,763,566 | 15 | -21.70% | $60.05M | |
$39,336,371 | 14 | -17.87% | $57.03M | |
$19,300,035 | 11 | 45.88% | $50.02M | |
$45,000,000 | 6 | -31.22% | $57.99M | |
$657,791 | 4 | -52.05% | $48.4M | |
$4,256,958 | 4 | 22.95% | $47.4M | |
$67,369,250 | 3 | -22.09% | $50.49M | |
$12,498 | 2 | 39.61% | $54.02M | |
$4,030 | 1 | 9.14% | $51.68M |
| Increased Positions | 9 | +42.86% | 65,844 | +72.11% |
| Decreased Positions | 6 | -28.57% | 4,945 | -5.42% |
| New Positions | 6 | New | 26,203 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 24 | +14.29% | 152,212 | +66.69% |
| Vanguard Group Inc | $371.00 | 0.67% | 33,351 | +9,607 | +40.46% | 2025-09-30 |
| Longbow Finance Sa | $185.00 | 0.33% | 16,667 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $162.00 | 0.29% | 14,600 | +14,600 | New | 2025-09-30 |
| Geode Capital Management, Llc | $142.00 | 0.26% | 12,806 | +1,314 | +11.43% | 2025-09-30 |
| Blackrock, Inc. | $70.00 | 0.13% | 6,298 | -1,123 | -15.13% | 2025-09-30 |
| Ubs Group Ag | $63.00 | 0.11% | 5,648 | +5,364 | +1,888.73% | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $10.00 | 0.02% | 926 | +926 | New | 2025-09-30 |
| Bank Of America Corp /De/ | $6.00 | 0.01% | 568 | 0 | 0% | 2025-09-30 |
| Covestor Ltd | $1.00 | <0.01% | 131 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $1.00 | <0.01% | 124 | +4 | +3.33% | 2025-09-30 |